Lipoatrophy in four children with type I diabetes
| Patient 1 | Patient 2 | Patient 3 | Patient 4 | |
|---|---|---|---|---|
| Age at diagnosis of T1DM (years) | 2 | 2 | 9 | 11 |
| Initial insulins (indicating the insulin associated with LA) | NovoMix 30 (LA) | NovoMix 30 (LA) | NovoRapid (LA)+Glargine | NovoRapid+Levemir (LA) |
| LA initially observed: age (years) | 4 | 5 | 12 | 14 |
| LA initially observed: year/month | 2006/November | 2007/September | 2006/August | 2008/May |
| HbA1c at onset of LA (%) | 9 | 8 | 9 | 11.4 |
| HbA1c after 3 months of resolution of LA (%) | 7.4 | 8 | 9 | 9 |
| LA resolved by changing sites | Yes | No | Yes | No |
| Change of insulin analogues | No | NovoMix 30 to Humalog Mix25 | No | Levemir to Glargine |
HbA1c, glycosylated haemoglobin; LA, lipoatrophy; T1DM, type I diabetes mellitus.